These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 3036033)

  • 1. Pure red cell aplasia associated with administration of sustained-release procainamide.
    Giannone L; Kugler JW; Krantz SB
    Arch Intern Med; 1987 Jun; 147(6):1179-80. PubMed ID: 3036033
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pure red cell aplasia in procainamide induced systemic lupus erythematosus. Report and review of the literature.
    Agudelo CA; Wise CM; Lyles MF
    J Rheumatol; 1988 Sep; 15(9):1431-2. PubMed ID: 3143834
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Procainamide in plasma following administration of sustained-release tablets in acute myocardial infarction.
    Ihlen H; Skomedal T; Stafsnes H; Ditlefsen EM
    Curr Ther Res Clin Exp; 1975 Mar; 17(3):257-62. PubMed ID: 805020
    [No Abstract]   [Full Text] [Related]  

  • 4. Thrombocytopenia following sustained-release procainamide.
    Meisner DJ; Carlson RJ; Gottlieb AJ
    Arch Intern Med; 1985 Apr; 145(4):700-2. PubMed ID: 2580499
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Procainamide in acute myocardial infarction: a study on two different tablet preparations of sustained release type.
    Ihlen H; Ditlefsen L
    Curr Ther Res Clin Exp; 1975 Nov; 18(5):720-6. PubMed ID: 812650
    [No Abstract]   [Full Text] [Related]  

  • 6. Chlorpropamide-induced pure RBC aplasia.
    Planas AT; Kranwinkel RN; Soletsky HB; Pezzimenti JF
    Arch Intern Med; 1980 May; 140(5):707-8. PubMed ID: 7396598
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Conventional and sustained-release procainamide: update on pharmacology and clinical use.
    Anderson JL
    Clin Ther; 1985; 7(5):618-40. PubMed ID: 3902240
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Serum concentrations of procainamide during treatment with ordinary and sustained-release tablets].
    Henningsen P; Laursen HB; Christiansen BD; Moller J
    Ugeskr Laeger; 1976 Sep; 138(40):2433-7. PubMed ID: 968997
    [No Abstract]   [Full Text] [Related]  

  • 9. [Oral administration of procainamide for ventricular arrhythmia. Plasma concentrations during use of tablets(Pronestyl) and a slow-release preparation (Porcainamide Durettes)].
    Bliddal J
    Ugeskr Laeger; 1976 Sep; 138(40):2425-33. PubMed ID: 968996
    [No Abstract]   [Full Text] [Related]  

  • 10. [Aplastic anemia following indomethacin therapy].
    Burghuber O
    Acta Med Austriaca Suppl; 1979; 6():384-6. PubMed ID: 122219
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Severe neutropenia associated with sustained-release procainamide.
    Ellrodt AG; Murata GH; Riedinger MS; Stewart ME; Mochizuki C; Gray R
    Ann Intern Med; 1984 Feb; 100(2):197-201. PubMed ID: 6691661
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Drug-polymer combinations. Part 1: The preparation of sustained release drugs by combination with ion exchanging resins.
    Gyselinck P; van Severen R; Braeckman P; Schacht E
    Pharmazie; 1981 Nov; 36(11):769-72. PubMed ID: 7323125
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Clinical study of ciclosporin in patients with aplastic anemia and pure red-cell aplasia].
    Kitamura K; Urabe A; Nomura T; Mizoguchi H; Takaku F
    Rinsho Ketsueki; 1995 Mar; 36(3):175-84. PubMed ID: 7783321
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Procainamide-induced pure red cell aplasia.
    Pasha SF; Pruthi RK
    Int J Cardiol; 2006 Jun; 110(1):125-6. PubMed ID: 16039734
    [No Abstract]   [Full Text] [Related]  

  • 15. Sustained-release procainamide: use of serum concentrations to determine dosage.
    Reed WE; Cooper MW
    South Med J; 1985 Oct; 78(10):1190-3. PubMed ID: 4049036
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Experiences on a sustained-release procainamide preparation.
    Ruosteenoja R; Torsti P; Sothmann A
    Curr Ther Res Clin Exp; 1973 Oct; 15(10):707-12. PubMed ID: 4201315
    [No Abstract]   [Full Text] [Related]  

  • 17. Sustained-release procainamide-induced reversible granulocytopenia after myocardial infarction.
    Abe H; Suzuka H; Tasaki H; Kuroiwa A
    Jpn Heart J; 1995 Jul; 36(4):483-7. PubMed ID: 7474364
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of a new sustained release procainamide preparation: evaluation with 24-hour Holter monitoring.
    Garcia JR; Godley ML; Freedman RJ
    J La State Med Soc; 1982; 134(1):8-9. PubMed ID: 7086265
    [No Abstract]   [Full Text] [Related]  

  • 19. [Steady-state plasma and saliva concentrations of procainamide and N-acetyl-procainamide after a sustained release preparation].
    Pirovino M; Karlaganis G; Galeazzi RL
    Schweiz Med Wochenschr; 1980 Sep; 110(39):1415-9. PubMed ID: 6169144
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Severe neutropenia due to sustained-release procainamide.
    Hoyt RE
    South Med J; 1987 Sep; 80(9):1196-7. PubMed ID: 3629327
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.